Physician profile
David Griffin
NPI 1508823618
$1,667.98
in general payments reported to CMS, 2019-2025
35 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $59.23 · 2021: $70.19 · 2022: $455 · 2023: $227 · 2024: $141 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $231.15 | 2022 | |
| Merck Sharp & Dohme LLC | $230.22 | 2019-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $129.70 | 2019-2024 | Lynparza |
| Taiho Oncology, INC. | $119.95 | 2019-2023 | |
| Eisai INC. | $103.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $95.26 | 2021-2023 | Zejula, Jemperli |
| Sun Pharmaceutical Industries INC. | $66.38 | 2019 | |
| Genentech USA, INC. | $64.65 | 2019-2022 | |
| Clovis Oncology, INC. | $58.37 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.34 | 2019-2022 | |
| Abbvie INC. | $47.25 | 2024-2025 | |
| Genmab U.S., INC. | $39.14 | 2021-2025 | Tivdak |
| Karyopharm Therapeutics INC. | $34.49 | 2020 | |
| Seagen INC. | $32.19 | 2019-2023 | Tukysa |
| Puma Biotechnology, INC. | $28.23 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.77 | 2019 | |
| Genzyme Corporation | $25.32 | 2023 | |
| Gilead Sciences, INC. | $24.18 | 2023 | Trodelvy |
| Daiichi Sankyo INC. | $22.21 | 2019 | |
| Jazz Pharmaceuticals INC. | $20.99 | 2022 | |
| Heron Therapeutics, INC. | $18.72 | 2022 | |
| G1 Therapeutics, INC. | $17.86 | 2022 | |
| Springworks Therapeutics, INC. | $16.63 | 2024 | Ogsiveo |
| Rigel Pharmaceuticals, INC. | $15.37 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.03 | 2019 | |
| Array Biopharma INC | $15.01 | 2022 | |
| Pfizer INC. | $14.42 | 2024 | |
| Incyte Corporation | $13.43 | 2019 | |
| Astellas Pharma US INC | $12.72 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $12.51 | 2019 | |
| Dova Pharmaceuticals | $12.39 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.36 | 2019 | |
| Celgene Corporation | $12.23 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.